For research use only. Not for therapeutic Use.
SOP1812（Cat No.:I036506）is an investigational small molecule compound being developed for its potential in treating autoimmune and inflammatory diseases, particularly those involving the central nervous system. It acts as a selective inhibitor of the enzyme Janus kinase 3 (JAK3), which plays a key role in immune cell signaling, particularly in T-cell activation and cytokine production. By inhibiting JAK3, SOP1812 can modulate immune responses and reduce inflammation. Preclinical studies suggest it may offer therapeutic benefits in conditions like rheumatoid arthritis, lupus, and potentially multiple sclerosis, with a focus on minimizing side effects associated with existing immunomodulatory therapies.
| Catalog Number | I036506 |
| CAS Number | 2546091-70-5 |
| Synonyms | SOP1812; SOP 1812; SOP-1812; |
| Molecular Formula | C45H58N8O6 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 14-hydroxy-6,13-bis(3-morpholin-4-ylpropyl)-10-(2-pyrrolidin-1-ylethylimino)-3-[4-(pyrrolidin-1-ylmethyl)phenyl]-6,13-diazatetracyclo[6.6.2.04,16.011,15]hexadeca-1(14),2,4(16),8,11(15)-pentaene-5,7,12-trione |
| InChI | InChI=1S/C45H57N7O6/c53-42-35-29-34(33-9-7-32(8-10-33)31-50-14-3-4-15-50)40-38-36(43(54)51(44(40)55)18-5-16-48-21-25-57-26-22-48)30-37(46-11-20-47-12-1-2-13-47)41(39(35)38)45(56)52(42)19-6-17-49-23-27-58-28-24-49/h7-10,29-30,53H,1-6,11-28,31H2 |
| InChIKey | TZQVPFRBHPQZNM-UHFFFAOYSA-N |
| SMILES | C1CCN(C1)CCN=C2C=C3C4=C(C(=CC5=C(N(C(=O)C2=C54)CCCN6CCOCC6)O)C7=CC=C(C=C7)CN8CCCC8)C(=O)N(C3=O)CCCN9CCOCC9 |
| Reference | 1: Ahmed AA, Angell R, Oxenford S, Worthington J, Williams N, Barton N, Fowler TG, O’Flynn DE, Sunose M, McConville M, Vo T, Wilson WD, Karim SA, Morton JP, Neidle S. Asymmetrically Substituted Quadruplex-Binding Naphthalene Diimide Showing Potent Activity in Pancreatic Cancer Models. ACS Med Chem Lett. 2020 Jul 16;11(8):1634-1644. doi: 10.1021/acsmedchemlett.0c00317. PMID: 32832034; PMCID: PMC7429975. |
